Optimizing Chemotherapy for Frail and Elderly Patients With Advanced Gastroesophageal Cancer

Share it with your friends Like

Thanks! Share it with your friends!


#ASCO19 #JAMAMedNews In the GO2 Phase III trial presented at the 2019 American Society of Clinical Oncology Meeting, lower-dose chemotherapy regimens (epirubin/oxaliplatin/capecitabine) were non-inferior to standard higher-dose regimens for patients with advanced gastroesophageal cancer. JAMA Associate Editor Deborah Schrag, MD, MPH of the Dana-Farber Cancer Institute in Boston explains the importance of the findings to JAMA News senior staff writer Jennifer Abbasi.


Write a comment